CPC C07K 14/7151 (2013.01) [A61K 9/0019 (2013.01); A61K 38/1793 (2013.01); A61K 47/26 (2013.01); A61K 47/68 (2017.08); C07K 19/00 (2013.01); A61K 47/02 (2013.01); A61P 29/00 (2018.01); C07K 14/525 (2013.01); C07K 14/70578 (2013.01); C07K 16/241 (2013.01); C07K 2319/30 (2013.01)] | 18 Claims |
1. A syringe comprising a composition, wherein the composition comprises:
an isolated polypeptide that is an extracellular ligand-binding portion of a human p75 tumor necrosis factor receptor fused to the Fc region of a human IgG1 at a concentration of 10 mg/mL to 100 mg/mL;
aqueous buffer at a concentration of less than 25 mM, wherein the aqueous buffer is sodium phosphate, potassium phosphate, sodium or potassium citrate, maleic acid, ammonium acetate, tris-(hydroxymethyl)-aminomethane (tris), acetate, diethanolamine, or a combination thereof;
salt at a concentration of greater than 100 mM; and
a sugar,
wherein the composition does not contain free amino acids.
|